Nkarta (NASDAQ:NKTX – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02, FiscalAI reports.
Nkarta Price Performance
NASDAQ NKTX traded up $0.10 during trading hours on Tuesday, hitting $3.28. The company had a trading volume of 500,445 shares, compared to its average volume of 821,878. The firm’s 50 day moving average is $2.56 and its 200 day moving average is $2.21. Nkarta has a fifty-two week low of $1.63 and a fifty-two week high of $3.65. The company has a market capitalization of $233.83 million, a price-to-earnings ratio of -2.34 and a beta of 0.88.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on NKTX shares. Mizuho reduced their target price on Nkarta from $14.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 31st. Wall Street Zen lowered shares of Nkarta from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a report on Friday, March 27th. Finally, Needham & Company LLC upped their price target on shares of Nkarta from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Nkarta has a consensus rating of “Hold” and an average target price of $11.33.
Institutional Investors Weigh In On Nkarta
Institutional investors and hedge funds have recently modified their holdings of the stock. Abel Hall LLC acquired a new stake in Nkarta during the 4th quarter valued at $27,000. Dynamic Technology Lab Private Ltd acquired a new position in Nkarta in the 4th quarter worth $37,000. Wells Fargo & Company MN boosted its position in Nkarta by 45.8% in the 4th quarter. Wells Fargo & Company MN now owns 47,997 shares of the company’s stock valued at $89,000 after buying an additional 15,079 shares during the last quarter. Man Group plc acquired a new stake in shares of Nkarta during the third quarter valued at about $90,000. Finally, Prelude Capital Management LLC acquired a new stake in shares of Nkarta during the third quarter valued at about $90,000. Hedge funds and other institutional investors own 80.54% of the company’s stock.
About Nkarta
Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.
Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.
Further Reading
- Five stocks we like better than Nkarta
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
